Kerlo Research Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$487,285	20
2024	Research	$474,907	23
2023	Research	$257,799	27
2022	Research	$45,051	6
2021	Research	$4,460	2
2020	Research	$92,651	24
2019	Research	$123,408	11

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $1,070,470 55 payments
Allergan Inc. $220,519 37 payments
Biohaven Pharmaceutical Holding Company Ltd. $83,822 11 payments
Braintree Laboratories, Inc. $50,495 4 payments
Davol Inc. $24,000 1 payment
Sumitomo Pharma America, Inc. $21,000 4 payments
Cleerly, Inc. $15,255 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents 6 to 18 Years of Age $1,091,908 59 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $147,857 13 payments
A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease $50,495 4 payments
A Phase 3 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 Years of Age $45,051 6 payments
A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $37,020 15 payments
Stance $24,000 1 payment
A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $17,333 1 payment
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $16,178 4 payments
Transform $15,255 1 payment
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $8,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.